Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease
Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Freezing of Gait (FoG) is a class of symptoms that occur in Parkinson's patients. Also called
motor blocks, FoG is characterized by a sudden inability to move the lower extremities which
usually lasts less than 10 seconds. The exact pathophysiology of FoG is poorly understood,
but treatment with levodopa appears to improve FoG observed in the off-state. As Parkinson's
patients progress in severity, FoG in the on-state can increase in frequency and appears to
be resistant to dopaminergic therapies. There is additional evidence that norepinephrine as
well as dopaminergic systems may be involved in FoG.
Droxidopa has has been approved for use in Japan since 1989 for treatment of frozen gait or
dizziness associated with Parkinson's Disease. This study is to further explore the safety
and efficacy of droxidopa in this indication.